肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)

Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion(2024 edition)

肝细胞癌(以下简称肝癌)是我国常见的恶性肿瘤之一,手术切除是首选的治疗方法,但术后复发转移率高。目前证据表明微血管侵犯(MVI)是导致肝癌复发转移的独立危险因素,但是目前国际上对于MVI的诊断、分型、预测和治疗仍存在较多争议。为更好地指导肝癌伴MVI的诊断和治疗,中国医师协会肝癌专业委员会组织国内相关领域专家,经过多次讨论和修改,形成《肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)》,以供国内同行参考。

Hepatocellular carcinoma(hereinafter referred to as liver cancer)is one of the most common malignant tumors in China.Surgical resection is the preferred treatment for liver cancer,but the postoperative recurrence and metastasis rates are quite high.Current evidence shows that microvascular invasion(MVI)is an independent risk factor for postoperative recurrence and metastasis of liver cancer,but there are still many controversies about the diagnosis,classification,prediction and treatment of MVI over the world.The Chinese Association of Liver Cancer of Chinese Medical Doctor Association organizes domestic experts in related fields to form the Chinese Expert Consensus on the Diagnosis and Treatment of Hepatocellular Carcinoma with Microvascular Invasion(2024 Edition)after many discussions and revisions,in order to better guide the diagnosis and treatment of Liver Cancer with MVI and for reference by domestic peers.